News Overview

Quant Biomarkers AG


Our approach leverage innovations in biomarker technology and AI modelling to address the growing healthcare challenges associated with aging populations, with an initial emphasis on chronic kidney disease (CKD). Our lead development candidate, RenoPredict®, is a CDSS (Clinical Decision Support System) Software as a Service (SaaS) product. It is a proprietary artificial intelligence model (AI/ML) that utilizes standard-of-care blood biomarkers to assist clinicians in predicting CKD disease progression. 

Additionally, we have recently licensed RenoRisk®, a novel urine-based biomarker panel championed by xKidney®, PoC product to enhance early and accurate detection of glomerular inflammation as an early sign of CKD development.  Likely to have applications in diagnosing and managing other chronic diseases within the cardio-renal-metabolic syndrome. 

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.